Delix is pushing the frontiers of neuroplasticity research to achieve selective re-wiring of pathological neural circuits.  As neural circuitry dysfunction is core to most brain disorders, the Delix platform has broad potential to address a range of diseases including treatment-resistant depression, substance use disorder, PTSD, cognitive impairment in schizophrenia, neurodegeneration, and many others.

Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, we are building a world class CNS company on a mission to broaden patient access to safe, fast-acting, and long-lasting medicines for many of the leading causes of disability worldwide.

Using our platform, we are developing a pipeline of distinct therapeutic assets tailored to specific disease indications.  By tuning novel molecules inspired by the structures of psychedelics, our compounds positively re-wire pathological neural circuitry but without the hallucinogenic and other side effects that have prevented ketamine and psychedelics from being deployed at scale.

Our scientific rigor has enabled us to build broad screening capabilities that include gold standard assays as well as innovative, cutting-edge technologies. We are advancing our portfolio of over 1,400 compounds based on > 8 unique chemical scaffolds.  Our first two assets are on track to be in the clinic in 2023, with several additional compounds not far behind.